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Abstract 
The anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV) are a heterogeneous 
group of diseases causing inflammation in small blood vessels and linked by the presence of 
circulating ANCA specific for proteinase 3 (PR3) or myeloperoxidase (MPO). These antigens are 
present both in the cytoplasmic granules and on the surface of neutrophils, and the effect of ANCA 
on neutrophil biology has been extensively studied. In contrast, less attention has been paid to the 
role of monocytes in AAV. These cells contain PR3 and MPO in lysosomes and can also express 
them at the cell surface. Monocytes respond to ANCA by producing pro-inflammatory and 
chemotactic cytokines, reactive-oxygen-species and by up-regulating CD14. Moreover, soluble and 
cell surface markers of monocyte activation are raised in AAV patients, suggesting an activated 
phenotype that may persist even during disease remission. The presence of monocyte-derived 
macrophages and giant cells within damaged renal and vascular tissue in AAV also attests to their 
role in pathogenesis.  In particular, their presence in the tertiary lymphoid organ-like granulomas 
of AAV patients may generate an environment predisposed to maintaining autoimmunity. Here we 
discuss the evidence for a pathogenic role of monocytes in AAV, their role in granuloma formation 
and tissue damage, and their potential to both direct and maintain autoimmunity. ANCA-
activation of monocytes may therefore provide an explanation for the relapsing-remitting course 
of disease and its links with infections.  Monocytes may thus represent a promising target for the 
treatment of this group of life-threatening diseases 
 
ANCA-associated vasculitides 
Anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV) are a group of rare 
systemic autoimmune diseases that affect small or medium-sized blood vessels. The term 
embraces three different nosologic entities: granulomatosis with polyangiitis (GPA, previously 
Wegener’s granulomatosis), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with 
polyangiitis (EGPA, previously Churg-Strauss syndrome), all of which are characterized by 
necrotizing vasculitic lesions with scanty or absent immune deposits and, for GPA and EGPA, by 
the presence of tissue granulomas, typically in the upper and lower respiratory tract [1]. Whilst 
there is significant clinical overlap between these diseases, each also demonstrates distinct 
pathological profiles.  Thus, GPA is characterized by disrupting lesions of the upper respiratory 
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tract, lung involvement, and, in approximately 70% of patients, a pauci-immune necrotizing 
glomerulonephritis (GN) with extra-capillary proliferation [2]. In MPA, the kidney is affected in 
almost 100% of cases [2], with alveolar hemorrhage affecting one third of patients [3]. In contrast, 
in EGPA the kidney is not a main target of disease, whilst lung involvement is almost constant. 
EGPA is commonly associated with asthma and eosinophilia, with eosinophil tissue infiltration 
contributing to lesion pathogenesis [4]. 
Despite these clinical disparities, AAV patients are linked by their serological positivity for ANCA. 
These IgG antibodies target two main proteins in neutrophils and monocytes, namely proteinase 3 
(PR3), a serine protease that on immunofluorescence assay shows a granular, cytoplasmic staining 
pattern (C-ANCA), and myeloperoxidase (MPO), which shows a peri-nuclear staining pattern (P-
ANCA) [5].  PR3 seropositivity is typically found in GPA patients (at least in Caucasians) [6], whilst 
MPA and EGPA are predominantly associated with anti-MPO antibodies [5]. 
ANCA positivity is not completely diagnostic, and some patients clinically diagnosed with AAV are 
ANCA negative, while low levels of ANCA can be detected in some healthy individuals [7].   In EGPA 
only about 40% of patients have ANCA [2], typically those with renal involvement and more 
vasculitic features [4], compared to 75-95% of active GPA and MPA [2]. On the other hand, there is 
good scientific evidence to suggest that ANCA are closely linked to disease pathogenesis [8], and 
variations in ANCA titres are used as a rough tool for monitoring vasculitis activity in clinical 
practice. However, ANCA titres do not correlate well with disease activity in all reported series, but 
can be more useful in renal AAV [9]. 
 
Evidence for the pathogenicity of ANCA 
Animal models of MPO AAV have been extremely useful and have demonstrated that, in mice and 
rats, IgG anti-MPO antibodies can cause necrotizing crescentic glomerulonephritis and systemic 
small vessel vasculitis [10, 11]. Attempts to establish an animal model of GPA by the direct 
injection of anti-PR3 antibodies into mice have been more problematic and have failed to induce 
any pathological changes, even after pre-treatment with LPS. Another approach using human-anti-
PR3 antibodies in mice with a humanized immune system, generated mild pulmonary capillaritis 
and glomerulonephritis, but did not reproduce the GPA phenotype and, in particular, failed to 
induce granulomatous lesions [12]. 
 
In humans, PR3-ANCA may appear before sub-clinical and clinical GPA [13], and their production is 
also associated with the development of drug-induced systemic vasculitis [9]. There is a 
correlation between ANCA titre and specificity with disease activity and phenotype respectively. 
ANCA pathogenicity is also demonstrated by the clinical benefit observed in AAV with treatment 
strategies aimed at removing circulating antibodies, such as plasmapheresis [14], or at hindering 
antibody production by depleting B lymphocytes, eg. rituximab [15] , and this approach forms a 
valuable part of AAV treatment today. Direct evidence for the pathogenic nature of ANCA in 
3  
 
humans has also been provided by a sporadic case of transplacental MPO-ANCA transfer from 
mother to baby, with the development of pulmonary and kidney vasculitis in the newborn [8]. 
 
 
ANCA can activate neutrophils  
The ANCA antigens MPO and PR3 are expressed in the azurophilic granules of neutrophils and the 
lysosomes of monocytes, but can also be expressed on the cell surface. Expression can be up-
regulated, at least in vitro, by priming with tumor necrosis factor α (TNFα) [16, 17]. 
TNFα-primed neutrophils respond to ANCA stimulation by releasing their granules and reactive-
oxygen-species (ROS), producing pro-inflammatory cytokines and increasing the expression of 
adhesion molecules on their surface, and they have been shown to activate and damage 
endothelial cells [18]. Moreover, ANCA induce neutrophils to release DNA, histones and proteins 
into the extracellular space as neutrophil extracellular traps (NETs), a phenomenon known as 
NETosis. This is primarily a mechanism of defense against infections, but could also be implicated 
in tissue injury and in the onset of autoimmunity in AAV, through PR3 and MPO presentation to 
antigen presenting cells [19]. The response of neutrophils to ANCA and their role in AAV has been 
discussed in many excellent reviews [19]. For the purpose of this review we will concentrate on 
the role of monocytes in AAV, an area of research which, to date, has received significantly less 
attention. 
 
Monocytes in inflammation and autoimmune diseases 
As one of the cell types expressing ANCA antigens, monocytes are prime candidates for mediating 
many of the systemic inflammatory effects seen in AAV. Their potential role in disease 
pathogenesis is only beginning to be elucidated, but a number of key observations suggest that 
these cells have an important role to play in AAV. Monocytes represent approximately 10% of 
human leucocytes in the blood stream and originate from the bone marrow.  Although they have 
traditionally been regarded as the progenitors of tissue macrophages, recent studies have 
revealed that, at least during homeostasis, many tissue-resident macrophage populations are 
maintained by a process of self-renewal [20]. In conditions of tissue insult, these cells undergo 
further rounds of proliferation, but their numbers are also boosted by the recruitment of 
monocytes from the circulation.  Once recruited, monocytes can differentiate into macrophages 
and are able to mediate a wide range of immunologic processes [20]. 
Monocytes are now recognized as a heterogeneous population, and can be divided into three sub-
types, according to the level of expression of two cell surface antigens, CD14 (the co-receptor for 
Toll-Like-Receptor (TLR)-4), and CD16 (FcγIIIR). Thus, monocytes are described as classical 
(CD14++/CD16-), intermediate (CD14++/CD16+), or non-classical (CD14dim/CD16+) [21].The 
distinctions between these groups are not completely defined, and they may represent a 
maturation continuum rather than clear-cut divisions [22]. Nevertheless, these sub-divisions are 
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backed-up by differences in phenotype, in cytokine production at homeostasis or in response to 
infections, in phagocytosis capability, in the internalization and presentation of antigens, in the 
ability to differentiate, and in trafficking and migration [23, 24]. 
 
Monocyte subsets in the context of human disease have been explored, and recent evidence has 
highlighted the possible role of the intermediate population in autoimmune disorders such as 
rheumatoid arthritis [25]. Observations from Tarzi et al [26] in our laboratory have also revealed 
differences in ANCA antigen expression between monocyte subsets in AAV patients and healthy 
controls, showing that classical and intermediate monocytes display the highest levels of PR3, 
whereas MPO is more highly expressed on intermediate monocytes. In AAV patients, both PR3 and 
MPO expression correlate with expression of CD14.  This observation suggests that distinct 
monocyte subsets may have different roles in the pathogenesis of AAV.  
 
ANCA activation of monocytes 
 
Challenge of monocytes with anti-PR3 and anti-MPO immunoglobulins elicits the production of the 
chemoattractant protein-1 (MCP-1) [27], and of a range of pro-inflammatory cytokines and 
prostanoids including TNFα, IL-1β, IL-8, IL-6 and thromboxane A2, [16]. In TNFα-primed cells, ANCA 
can evoke an increase in ROS production [17]. This allows monocytes to participate in leucocyte 
recruitment and the development of local inflammation. With regard to the mechanisms that lead 
from ANCA-antigen interaction to the effects observed in monocytes, it has been speculated that 
the recognition of surface PR3 or MPO by the antigen binding site of the autoantibodies may be 
sufficient for responses such as ROS production [17] or CD14 up-regulation [18], as demonstrated 
by a preserved or reduced response to the Fab2 fragment of ANCA. However, for cytokine release 
concurrent cross-linking of surface Fcγ receptors may be necessary [28].  
 
Monocytes in AAV – changes in monocyte physiology 
A number of studies have described significant changes in the phenotype and activity of circulating 
monocytes in AAV patients. GPA patients show an increase of neopterine levels, (a soluble marker 
of monocyte/macrophage response to interferon (INF)-γ), and a correlation of neopterine and 
interleukin (IL)-6 levels with disease activity [29]. Circulating monocytes in GPA patients also show 
increased expression of membrane molecules such as CD63 (a degranulation marker), and CD64 (a 
high affinity Fcγ receptor, crucial in innate immunity) [29]. Moreover, higher levels of integrins, 
namely CD29, CD18, CD11a, CD11b, that are essential for leucocyte-endothelium interaction and 
leucocyte diapedesis, have also been demonstrated [30], suggesting that monocytes in AAV could 
be more prone to cause tissue damage through an increased ability to interact with activated 
endothelial cells [31]. Soluble monocyte activation markers, such as MCP1α and VEGF, that reflect 
systemic chemotactic and inflammatory activity and endothelial activation, show significantly 
higher levels in patients with acute disease [32]. Monocyte CD11b up-regulation has been shown 
to persist in quiescent phases of disease [32], and recent studies have demonstrated that 
monocytes from patients with active AAV, as well as from PR3 positive patients in remission, 
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express increased levels of CD14, suggesting that these cells may be more susceptible to TLR4-
mediated activation [26]. It could therefore be argued that a certain degree of monocyte 
activation persists during remission, which may account for the relapsing-remitting character of 
GPA. 
 
Monocytes in AAV-histological observations 
ANCA-associated glomerulonephritis 
Kidney involvement in AAV is a frequent event and is characterized histologically by focal necrosis 
of glomerular capillaries with extra-capillary proliferation and pauci-immune-staining on 
immunofluorescence [2]. Leucocyte infiltration of the tubulo-interstitial area is often present and, 
especially in the proximity of the glomeruli, it can be organized to form pseudo-granulomatous 
structures where giant cells can be found [33]. 
CD68+ monocytes/macrophages are the dominant infiltrating cell type in early biopsies of ANCA-
associated glomerulonephritis (ANCA GN), where they infiltrate apparently normal glomeruli, as 
well as being present in well-developed lesions (Figure 1) [34]. Accordingly, monocyte 
chemoattractant protein-1 (MCP-1), an important chemokine for monocyte recruitment, is 
increased in kidney biopsies of AAV and its levels in the urine correlate with glomerular disease 
activity [35]. 
 
The early presence of these cells suggests that they may be important in the initiation of kidney 
damage, as they are considered relevant in the promotion of fibrinoid necrosis, cellular crescent 
development, and for recruiting the T lymphocytes, which, together with macrophages, dominate 
the later stages of ANCA GN [36]. CD68+ cells are also present in kidney biopsies of AAV patients 
with established disease, where they localize preferentially to the sites of active glomerular 
lesions, including crescents, areas of fibrinoid necrosis, peri-glomerular infiltrates and granulomas 
[33]. Moreover, it was recently shown that renal infiltrating CD68+ cells in ANCA GN display 
positivity for MPO and can produce extracellular-traps containing MPO, further contributing to 
tissue damage and MPO antigen presentation [37]. CD68+ cells recruited to the kidney during 
vasculitic inflammation are thus closely associated with damage initiation and progression.  
 
Monocytes/macrophages in ANCA GN display an activated phenotype, showing MHC Class II up-
regulation and intense calprotectin expression when compared to healthy controls [33]. The latter 
molecule is expressed by macrophages in active proliferative GN of different etiologies [38]. In 
AAV kidney biopsies, calprotectin is a marker of acute glomerular lesions, and thus associated with 
better renal prognosis in treated cases [39]. Calprotectin is also a key molecule for the 
amplification of inflammatory processes. Pro-inflammatory stimuli promote calprotectin 
translocation to the cellular membrane and its systemic release from neutrophils, monocytes and 
early macrophages. In turn, calprotectin induces cytokine and chemokine release, and tissue 
damage, generating an autocrine inflammatory response [40]. Serum levels of calprotectin are 
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raised in active AAV and remained elevated after treatment in patients that relapse [39]. 
Consistent with this observation, it has recently been demonstrated in an animal model of 
nephrotoxic nephritis that calprotectin may induce renal injury through its effects on macrophages 
[40]. 
 
Monocytes and granulomas in AAV 
While in other granulomatous diseases, such as tuberculosis, granuloma formation represents a 
mechanism to isolate and contain the infection, the pathophysiology of granulomas in GPA is still 
unclear.  Cells inside the granuloma are organized in a complex structure that favors contact and 
communication between cells of the adaptive and innate immune systems. In the GPA granuloma, 
PR3 containing cells (neutrophils and monocytes) are surrounded by antigen presenting cells, T 
cells, and B cells, organized in a pseudo-follicular manner as in lymphoid tissues [41]. The typical 
architecture of a granuloma consists of an external layer of T lymphocytes and an inner layer of 
macrophages, which eventually fuse to form multi-nucleated giant cells (MNGC) [42].  
Monocytes may play a key role in orchestrating the immunologic response in this setting. They can 
interact with ANCA and be activated in the blood stream. Following chemotactic signals, they can 
be recruited to the granuloma site, where they can interact with T cells and differentiate into 
macrophages [42]. Once in the granuloma, macrophage-derived molecules such as osteopontin 
may perpetuate the mobilization of new monocytes from the peripheral blood, thus generating a 
destructive cycle of cell recruitment and activation [42]. Indeed, MNGCs with an osteoclast–like 
phenotype have been demonstrated within GPA lesions, and are thought to further mediate tissue 
destruction by the production of cathepsin K and tartrate-resistant acid phosphatase (TRAP) [43]. 
The peculiar microenvironment created by the granuloma may therefore act as a tertiary 
lymphoid organ, capable of skewing both the local and systemic immune response on a short or 
long term basis, and it has been suggested that this is the site where tolerance is broken [44]. 
Thus, monocytes in granulomas may be critical in shaping the local and systemic T cell response in 
AAV. 
 
T cells in AAV and their interaction with monocytes 
Abnormalities of circulating T cells have also been described in GPA patients. In particular, GPA 
patients show an expanded memory T cell population, a deficiency in Tregs and persistent T cell 
activation. Of particular interest is the demonstration that the Th17 population in GPA is expanded 
in both active disease and in remission [45], and autoantigen-specific memory T cells producing IL-
17 are elevated in AAV in remission [46].  
The role of Th17 cells in autoimmunity is supported by an increasing body of evidence 
demonstrating their pro-inflammatory effects, their ability to promote innate immune activation, 
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and their function, together with their product IL-17, in mediating local damage and the formation 
of auto-reactive germinal centers in granulomas [47].  
Th17 T cells are described in GPA granulomas [48] and their generation may occur within the 
granuloma environment where monocytes and CD4+ T cells are in close proximity. Indeed, 
monocytes activated by TLR ligands or derived from non-lymphoid inflammatory sites have been 
shown to induce Th17 commitment of T cells in rheumatoid arthritis [49], suggesting that a similar 
event may occur in GPA granulomas. The ability of activated monocytes to interact with T cells, 
promote their recruitment and polarization, and modulate their activation, has also been 
demonstrated in rheumatoid arthritis [50]. 
The hypothesis of granuloma-mediated breakdown of tolerance is consistent with the natural 
history of GPA, where disease often begins as granulomatous lesions of the respiratory tract and 
may later evolve into systemic vasculitis. The environment within the GPA granulomas may 
therefore be the power house where monocytes redirect the T cell response [42], and push it 
towards pro-inflammatory Th17 cell production.   
Do infectious agents link monocytes and AAV? 
A significant body of evidence suggests that there is a link between AAV and infections. The 
antibiotic cotrimoxazole, for example, is successful in reducing the relapse rate in GPA [51], 
infections can trigger the acute phase of vasculitis, and nasal carriers of S. Aureus are more prone 
to relapse [52]. These in vivo findings are boosted by a significant amount of in vitro data 
examining the effect of pro-inflammatory cytokines, DAMPs, PAMPs and ANCA on monocyte 
activation.  
 
Thus, TNFα, as produced in infectious diseases, has been shown to up-regulate MPO and PR3 
expression on the monocyte cell surface, sensitizing them for interaction with ANCA [17]. 
Monocyte exposure to PR3-ANCA markedly increases their response to microbial antigens (Figure 
2).  Hattar et al. [52] for example, found that pre-incubation of monocytes with anti-PR3 
antibodies increased the production of IL-8, TNFα and IL-6 in response to LPS, and of IL-8 upon 
stimulation with lipoteichoic acid (LTA), constituents of the Gram-negative outer membrane and 
Gram-positive cell wall respectively. This effect seems to depend on the ANCA-mediated up-
regulation of the TLR4 co-receptor CD14 [52], an observation recently confirmed in vivo by Tarzi et 
al [26] who described raised levels of CD14 on circulating monocytes from PR3 patients both 
during active disease and in remission. Moreover CD14 expression correlated with ANCA antigen 
expression on monocytes of AAV patients, showing a stronger correlation with PR3 than MPO. The 
increased synthesis of CD14 in response to ANCA of both specificities (MPO and PR3) was also 
noted in another study, where it was concomitant with increased expression of the integrin CD18 
[18]. Some, but not all [52], workers have shown that TLR and NOD (1 and 2) expression may be 
up-regulated in PR3-ANCA challenged monocytes and in monocytes from AAV patients, 
particularly in S. Aureus nasal carriers [53, 54]. 
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The results described above suggest that both LPS stimulation during infections, and ANCA 
challenge in AAV, may use CD14 as a common mechanism of monocyte activation. The persistent 
up-regulation of CD14 on monocytes in PR3-AAV patients in remission may reflect a long-lasting 
activation of monocytes in GPA sustained by persistent nasal/upper airway infection, thereby 
predisposing GPA patients to more frequent relapses than in MPA [26]. Increased monocyte CD14 
levels may also have particular relevance to the recently described increased level of the TLR4 
ligand, calprotectin, in AAV patients [39].  Calprotectin is necessary to promote auto-reactive IL-17 
producing CD8+T cell development in a mouse model of systemic autoimmune disease, suggesting 
that its presence favours the onset and amplification of auto-reactivity [55]. The LPS, TNFα, IL-1β, 
and INFγ, produced during infections, or in inflammatory states such as AAV, may therefore be 
responsible for driving calprotectin release and contributing to persistent autoimmunity in this 
disease [40].  
 
In summary, monocytes in GPA patients may display a state of pre-activation, due to PR3-ANCA 
mediated sensitization, that amplifies their response to secondary stimuli with microbial antigens. 
The increased production of TNFα during infectious events leads to a rise in PR3 surface antigens, 
which exposes monocytes to the effect of anti-PR3 ANCA, and triggers the recruitment of other 
inflammatory cells, local damage and amplification of the immune response. Infectious agents also 
up-regulate calprotectin, which participates in the vicious circle of uncontrolled inflammation and 
auto-reactivity. Moreover, local inflammation/infection and the ensuing monocyte activation that 
persists in the remission phase of GPA may have a role in determining the predisposition to 
relapse (Figure 2). 
 
Would therapeutic targeting of monocytes be beneficial in AAV? 
Taken together, there is a significant body of evidence to suggest that monocytes act at different 
levels in the pathogenesis of AAV, and that they could provide a promising target in the 
development of new therapeutic strategies (Table 1). However, significant depletion of the 
monocyte pool would severely affect innate immunity with a corresponding increase in 
susceptibility to sepsis. Targeting of specific monocyte subsets has been proposed, but a clear 
pathogenic subgroup has not yet been delineated in AAV, and our understanding of the plasticity 
and consequent dynamic phenotype of monocytes is still in its infancy [24]. A fascinating 
therapeutic development in this direction could consist of “reprogramming” monocytes, possibly 
via epigenetic mechanisms. Recent insights into natural immunity suggest that modification of 
histone methylation or acetylation in monocytes may form the biochemical basis for the specific 
memory of innate immunity and for the shaping of monocyte phenotype. Although the clinical use 
of “epigenetic drugs” is to date mostly restricted to hematology and oncology [56], histone 
deacetylase inhibitors have proved beneficial in several animal models of inflammatory diseases 
[57], and could perhaps be used in AAV to modulate surface ANCA antigen expression and down-
regulate monocyte activation molecules during remission. 
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 Treatments designed to hinder the persistent activation of monocytes in AAV could also provide 
significant benefit for maintaining remission in AAV patients. CD14 and calprotectin are involved in 
the crosstalk between immune responses to infections and autoimmunity, and may play a pivotal 
role in the amplification of uncontrolled inflammation in AAV. Both of these molecules remain up-
regulated in AAV in remission [26, 39]. Anti-CD14 monoclonal antibodies (MAb) treatments, alone 
or coupled with complement inhibition, are being investigated in the intensive care setting as a 
method of reducing the uncontrolled inflammatory response and its detrimental effects in severe 
sepsis [58, 59, 60] and their effect in AAV may be worth investigating. On the other hand, 
quinoline-3-carboxyamide, an inhibitor of the calprotectin subunit S100A9, has proved effective as 
an immune-modulator in some animal models of autoimmune disease, and preliminary clinical 
data are available with regard to its use in diverse autoimmune diseases, such as multiple 
sclerosis, and systemic lupus erythematous [61, 62]. This approach could also have clinical 
applicability in AAV. 
 
With regard to granulomas, MNGC are a source of degrading enzymes and tissue damage in AAV. 
Identifying the molecular mechanisms involved in monocyte-macrophage multi-nucleation and 
MGGC formation would be required to inform the development of therapies designed to prevent 
the development of disrupting lesions in GPA. An example is the gene Kcnn4, recently 
characterized in rat macrophages, inhibition of which proved beneficial for renal lesions in a model 
of nephrotoxic nephritis [63]. 
Hampering monocyte migration to the target organs could be useful for the treatment of early 
stage ANCA GN. Inhibition of the chemokine CCL2/MCP-1 or its receptor CCR2 has already been 
tested in animal models of renal diseases, including crescentic GN, where reduced 
monocyte/macrophage infiltration was coupled with better histology and clinical parameters [64, 
65]. Various inhibitors of the CCR2-CCL2/MCP-1 axis have been proposed for clinical trials in 
different diseases, but not yet for ANCA GN [66]. Inhibition of leucocyte integrins or adhesion 
molecules is an alternative strategy [65]. For example neutralizing antibodies to LFA-1/ICAM-1 
[65], or VLA-4 (CD49b/CD29) reduced renal injury in crescentic GN in rats [67]. 
Lastly, targeting monocyte pro-inflammatory products is a feasible strategy. IL-6 is increased in 
active AAV patients’ sera and at the sites of active lesions (ANCA GN and skin vasculitis) and the 
inhibition of IL-6 receptor with a humanized monoclonal antibody, tocilizumab, was effective in 
patients with allergy to or refractory to standard therapy [68]. Both IL-1 and TNFα have a 
pathologic role in AAV. Activated monocytes/macrophages in kidney biopsies of ANCA GN stain 
positive for TNFα and IL-1 [33]. Both of these cytokines were demonstrated to mediate glomerular 
damage in experimental models of crescentic GN, where disease was prevented or halted by 
means of IL-1 receptor antagonists [69, 70] or TNFα blockade [71]. Inhibiting TNFα action would 
also prevent monocyte (and neutrophil) priming. Different anti-TNFα monoclonal antibodies could 
therefore have utility in the induction phase of treatment and in refractory cases, although 
attention has to be paid to the risk of serious infections [72, 73, 74]. Several IL-1 blockers, such as 
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anakinra, canakinumab (anti-IL1β neutralizing antibody), or rilonacept (soluble decoy receptor) 
have been approved for clinical use in several autoinflammatory and autoimmune disorders, and 
could represent a potential field of investigation for use in AAV [75].  
 
Monocyte-macrophage derived IL-23 is a recognized pro-inflammatory mediator in autoimmunity, 
promoting Th17 differentiation. In GPA patients IL-23 is found in granuloma biopsies and IL-23 
serum levels correlate with disease severity [76].  A drug targeting the p40 subunit of IL-23, 
(common to IL-23 and IL-12), has already been approved for psoriasis treatment, and is under 
investigation for use in other autoimmune diseases. Development of new molecules more specific 
for IL-23 inhibition is under way [77].      
 
To conclude, over the last decade there has been a growing awareness of the pivotal role of 
monocytes in the pathophysiological mechanisms of AAV. Further investigation of monocytes, to 
understand their regulatory mechanisms, better characterize the different subsets, and determine 
their role in inflammatory/autoimmune diseases, is warranted to develop new, more specific, 
therapeutic targets for AAV. 
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Figure legends 
Figure 1. ANCA-associated glomerulonephritis (ANCA GN) 
Hematoxylin and eosin staining and CD 68 immunohistochemistry of kidney biopsies from two 
patients with ANCA GN. 
CD68+ monocytes/macrophages are the dominant infiltrating cell type in patients with early ANCA 
GN, where they infiltrate apparently normal glomeruli and early lesions (A). 
 CD68+ cells are also present in biopsies of patients with established ANCA GN, where they localize 
preferentially to the sites of active glomerular lesions, including crescents, areas of fibrinoid 
necrosis, peri-glomerular infiltrates and granulomas (B). 
 
Figure 2. Monocytes at the axis between infectious diseases and AAV 
The amplification loop in AAV leads to  raised production of ROS, an increased recruitment of 
inflammatory cells, (mediated by the release of MCP-1 and IL-8), and a rise in the production of 
inflammatory cytokines, that may perpetuate and spread the phlogistic process. Other cytokines 
may be involved in the commitment of Th17 cells, mediating inflammation, local damage and 
promoting auto-immunity.  
(1) Monocytes in homeostatic conditions express low levels of ANCA antigens.  
(2) During infections, PAMPs together with pro-inflammatory cytokines and DAMPs activate 
monocytes, raising CD14 levels and ‘priming’ monocytes by inducing increased surface expression 
of ANCA antigens. In response to these stimuli, monocytes also produce calprotectin and TNFα 
that amplify in an autocrine manner their activation.   
(3) ANCA interaction with ANCA antigens and Fc receptors on monocytes causes further activation 
with increased CD14 expression.  
(4) Monocytes expressing increased ANCA antigens and CD14 respond to ANCA and CD14-
dependent PAMPs, producing increased pro-inflammatory cytokines. Chemokine production 
(MCP-1, IL-8) attracts additional leucocytes, thereby perpetuating the cycle of monocyte activation 
and pro-inflammatory mediator production and amplifying the inflammatory process.  
The alternative pathway of complement is also activated, further contributing to the inflammatory 
response (omitted for clarity). 
 
Abbreviations: ANCA, anti-neutrophil cytoplasm antibody; TNFα, tumor necrosis factor alpha; 
PAMPs, pathogen associated molecular patterns; LPS, lipopolysaccaride; DAMPs, danger 
associated molecular patterns; TNFαR, tumor necrosis factor alpha receptor; TLR, toll-like 
receptor; ROS, radical oxygen species; IL-1, interleukin 1; IL-6, interleukin 6; MCP-1, monocyte 
chemotactic protein 1; IL-8, interleukin 8; Th 17, T helper 17 cells. 
 
 
